When good drugs go bad

被引：213

作者：

Giacomini, Kathleen M. ^{[1
]}

Krauss, Ronald M.

Roden, Dan M.

Eichelbaum, Michel

Hayden, Michael R.

机构：

[1] Univ Calif San Francisco, Dept Biopharmaceut Sci, San Francisco, CA 94143 USA

[2] Childrens Hosp Oakland, Res Inst, Oakland, CA 94609 USA

[3] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA

[4] Stuttgart Inst Klin Pharmakol, Stuttgart, Germany

[5] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada

[6] Univ Tokyo, Tokyo, Japan

来源：

NATURE | 2007年 / 446卷 / 7139期

关键词：

D O I：

10.1038/446975a

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

07 ; 0710 ; 09 ;

摘要：

How can we best reduce the risk of severe adverse reactions to marketed drugs? An international group of scientists argues that a global research network is needed to identify genetically at-risk populations.

引用

页码：975 / 977

页数：3

共 18 条

[1]

Lazarou J(1998)undefined J. Am. Med. Assoc. 279 1200-1205

[2]

Pomeranz BH(2006)undefined Drug Saf 29 161-168

[3]

Corey PN(2006)undefined Toxicol. Mech. Meth. 16 89-99

[4]

van der Hooft CS(1969)undefined Pharmacol. Rev. 21 73-103

[5]

Huang SM(2006)undefined Ann. Intern. Med. 145 749-757

[6]

Beutler E(2006)undefined Drug Saf 29 385-396

[7]

Roden DM(2006)undefined Pharmacogenomics 7 633-638

[8]

Hazell L(2003)undefined Toxicology 192 37-48

[9]

Shakir SA(2006)undefined Annu. Rev. Med. 57 119-137

[10]

Molokhia M(2004)undefined N. Engl. J. Med. 350 1013-1022

← 1 2 →